- US-listed companies
- Cue Biopharma, Inc.
- Income statement
Cue Biopharma, Inc. (CUE) Income statement
Market cap
$1.3B
P/E ratio
| 2018/12 | 2019/12 | 2020/12 | 2021/12 | 2022/12 | 2023/12 | 2024/12 | |
| Revenue | 1 | 3 | 3 | 15 | 1 | 5 | 9 |
| Revenue growth (%) | - | ||||||
| Research & development | 29 | 27 | 34 | 41 | 39 | 41 | 36 |
| Operating margin (%) | |||||||
| Operating expenses | 40 | 40 | 48 | 59 | 54 | 58 | 51 |
| Operating income | -38,696,658 | -36,769,247 | -45,042,585 | -43,712,073 | -53,224,809 | -52 | -41 |
| Income before tax | -38,155,313 | -36,286,457 | -44,578,671 | -43,666,175 | -53,010,382 | - | - |
| Pretax margin (%) | -3,339.3 | -1,049.2 | -1,413.3 | -292.3 | -4,257.1 | - | - |
| Provision for income taxes | 825,000 | 412,500 | 206,250 | 495,000 | - | - | - |
| Effective tax rate (%) | - | - | - | ||||
| Net income | -38,980,313 | -36,698,957 | -44,784,921 | -44,161,175 | -53,010,382 | -51 | -41 |
| Net income margin (%) | |||||||
| Earnings per share | - | - | - | - | -1.49 | -1.11 | -0.72 |
| Diluted EPS | - | - | - | - | -1.49 | -1.11 | -0.72 |